Stago
Diagnostica Stago is a France-based pure-play provider of hemostasis and thrombosis diagnostic instruments, reagents, and quality control solutions for clinical laboratories and hospitals, operating in 115 countries with €550 million in 2025 revenue.
- Company typePrivate
- Founded1945
- HeadquartersAsnières, France
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Stago does
Diagnostica Stago is a France-based, privately held in vitro diagnostics company founded in 1945 in Asnières-sur-Seine and described as the only pure-play hemostasis analysis company globally. It develops, manufactures, and commercializes instruments, reagents, and quality control solutions for blood coagulation (hemostasis) and thrombosis testing, organized around the Max Generation analyzer suite (including the STA-WorkCell Max), the ST Genesia platform, the Platelet Aggregation Line (TA 4-V3 and TA 8-V3 Thrombo-Aggregometers), and the sthemO instrumentation range. Specialized offerings include the ISO/IEC 17043-accredited sthemE Qualiris external quality assessment program, My Expert QC peer-comparison software, MyOptiLab workflow optimization, Anti-Xa reagents for heparin monitoring, and CY-QUANT MV-TF Activity for microvesicles testing, complemented by digital ecosystem assets such as the My Personal Space customer portal and the iHemostasis and Haemoscore mobile applications.
Stago sells to clinical laboratories and hospitals worldwide through direct sales affiliates in key markets (including the US, Germany, Italy, UK, China, and Brazil) and a distributor network covering 115 countries, with 15+ country-specific websites supporting local commercial operations. Its commercial moat rests on 80+ years of single-domain focus, an installed base of analyzers that drives recurring reagent and consumable revenue, and complementary sub-brands such as Agro-Bio (custom antibody development), Tcoag, BioCytex, Synapse, Thrombinoscope, and HemoSonics (point-of-care hemostasis). Following its 2025 acquisition by ARCHIMED Diagnostics (MED Platform II) and minority investor La Caisse (formerly CDPQ) from the founding Viret family, Stago reported €550 million in 2025 revenue, transitioned CEO leadership to long-tenured executive Philippe Barroux, and announced plans to accelerate internationalization and product expansion under the MedValue template.
Stago firmographics
Firmographics- Name
- Stago
- Legal name
- Diagnostica Stago
- Website
- https://stago.com
- Company type
- Private
- Founded year
- 1945
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Diagnostica Stago is a France-based pure-play provider of hemostasis and thrombosis diagnostic instruments, reagents, and quality control solutions for clinical laboratories and hospitals, operating in 115 countries with €550 million in 2025 revenue.
- Ownership category
- akta.pro rank
Stago industry classification
Industry- Product category
- In Vitro Hemostasis Diagnostics
- NAICS
- Medical Laboratories (621511), Surgical and Medical Instrument Manufacturing (339112), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hematology & Coagulation Laboratories (HLAFAMAC)
- akta.pro secondary industry
- Clinical Chemistry, Hematology & Coagulation Testing (Trial Support) (HLAGAEAE)
Keywords
Where Stago is headquartered
LocationHeadquarters
- HQ city
- Asnières
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Stago business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Hemostasis Diagnostics Instruments and Reagents: Sale of specialized instruments and reagents for blood coagulation analysis to clinical laboratories and hospitals worldwide. Revenue generated from €550 million in 2025.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Stago product offering
Product offeringCore offering
Stago develops, manufactures, and supplies diagnostic instruments, reagents, and quality control solutions specialized in hemostasis and thrombosis testing for clinical laboratories and hospitals worldwide. Its portfolio spans the Max Generation analyzer suite, ST Genesia platform, TA-4V3/TA-8V3 Thrombo-Aggregometers, sthemO instrument line, the sthemE Qualiris external quality assessment program, and reagent products such as Anti-Xa and CY-QUANT MV-TF Activity.
Product overview
Stago is a global leader in blood coagulation (hemostasis) analysis, operating as the only pure-play hemostasis company globally with €550 million in revenues in 2025. The company offers a comprehensive portfolio of instruments and reagents for hemostasis testing, organized around the Max Generation suite of analyzers and the sthemO instrumentation line. The core platform is complemented by specialized modules including ST Genesia for analysis and quality control, sthemE Qualiris for external quality assessment (EQA) and My Expert QC for internal quality control comparison. Key products include the TA 4-V3/TA 8-V3 Thrombo-Aggregometer for platelet function testing, and the CY-QUANT MV-TF Activity assay for microvesicles analysis. The company also operates several sub-brands including Agro-Bio (custom antibodies and immunology services), Tcoag, BioCytex, Synapse, and HemoSonics. Digital offerings include the My Personal Space customer portal, MyOptiLab optimization tool, mobile applications iHemostasis and Haemoscore, along with educational content through podcasts and webinars.
Differentiator
Problem solved
Functional benefit
Products and services
- Stago Max Generation Analyzers A suite of hemostasis analyzers (including the STA-WorkCell Max system) designed to support blood coagulation testing across all laboratory environments. Sold to clinical laboratories and hospitals.
- ST Genesia Instrument system and hemostasis reagent platform for comprehensive hemostasis analysis, including thrombin generation testing, with associated quality control management. Sold to clinical laboratories.
- TA 4-V3 / TA 8-V3 Thrombo-Aggregometer Compact, easy-to-use, reliable and connectable thrombo-aggregometer for platelet function testing, available in 4-channel (TA 4-V3) and 8-channel (TA 8-V3) configurations. Sold to clinical laboratories and hospitals performing platelet function testing.
- sthemE Qualiris International external quality assessment (EQA) programme and inter-laboratory comparison (ILC) service for hemostasis testing, ISO/IEC 17043 accredited. Sold to clinical laboratories participating in proficiency testing.
- sthemO Hemostasis Instruments and Reagents New range of hemostasis instruments and reagents designed to meet evolving laboratory needs. Sold to clinical laboratories and hospitals.
- Anti-Xa Heparin Monitoring Reagent Reagent for precision monitoring of heparin therapy, providing improved accuracy over the aPTT method. Sold to clinical laboratories performing anticoagulation monitoring.
- CY-QUANT MV-TF Activity Assay Assay for microvesicles analysis, standardized and compliant with international guidelines. Sold to clinical laboratories performing specialized coagulation research and diagnostics.
- My Expert QC Quality control management software enabling users to compare internal quality control results with peers on any instrument of the STA range. Sold to clinical laboratories as a subscription/comparison service.
Companies that use Stago
Customer profileSegments1 record
Ideal customer profiles1 record
Stago technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature11 records
Stago partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered subsidiary.
- Agro-BiosubsidiaryAgro-Bio is a Stago Group company specializing in custom antibody development and immunology services for diagnostics and biopharma applications. Located in La Ferté Saint-Aubin, France.
- BioCytexsubsidiaryBioCytex is a specialty brand under the Stago Group focused on specialized diagnostics products.
- SynapsesubsidiarySynapse is a specialty brand under the Stago Group.
- TcoagsubsidiaryTcoag is a specialty brand under the Stago Group.
- ThrombinoscopesubsidiaryThrombinoscope is a specialty brand under the Stago Group, associated with the ST Genesia product line.
- HemoSonicssubsidiaryHemoSonics is a specialty brand under the Stago Group.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Stago competitors and assessment
Company assessmentBroad incumbents
- Siemens Healthineers: Siemens Healthineers offers the BCS/XP and CN hemostasis analyzer families as part of its broader IVD portfolio (central lab, POC, specialty). It competes head-to-head with Stago in hospital and reference labs, with bundling and service-scale advantages that a pure-play cannot match.
- Roche Diagnostics: Roche's cobas t hemostasis analyzers (including t 511/t 711) are installed in large hospital and reference lab networks. As the global IVD leader, Roche bundles hemostasis with chemistry/immunoassay, putting Stago at a disadvantage in multi-vendor consolidation decisions.
- Abbott Diagnostics: Abbott provides hemostasis testing on its Architect/ci-series platforms as part of a broad immunoassay/chemistry menu, competing with Stago in mid- to high-volume hospital labs.
Direct peers
- Werfen (Instrumentation Laboratory): Werfen's Instrumentation Laboratory (IL) division sells the ACL TOP family of hemostasis analyzers and Hemochron POC systems, the most direct global competitor to Stago's STA/Max Generation line, with a similar specialty positioning.
- Sysmex Corporation: Sysmex markets the CS- and CA-series hemostasis analyzers globally and is highly entrenched in hematology labs, often displacing pure-play hemostasis vendors in integrated lab automation deals.
- Helena Laboratories: Helena manufactures hemostasis reagents and instruments (AggRAM, Cascade) and competes with Stago in mid-volume hemostasis labs, particularly in North America.
Emerging players
- Trinity Biotech: Trinity Biotech focuses on hemostasis reagents and specialty diagnostics, including a hemostasis analyzer line, and is a smaller specialty competitor with overlap in reagent menus.
- Mindray: Mindray offers hemostasis analyzers (e.g., ExC and CS series) in the mid-tier segment, expanding aggressively outside China as a cost-competitive alternative to Stago.
Others
- QuidelOrtho: QuidelOrtho is an adjacent specialty diagnostics and transfusion medicine company, overlapping with Stago's platelet function and transfusion-related testing product lines.
- Bio-Rad Laboratories: Bio-Rad supplies quality controls, standards, and lab diagnostics consumables (e.g., in hemostasis QC) that overlap with Stago's My Expert QC and Qualiris programs.
Market position
Competitive moat6 records
Customer concentration
Stago social profiles
Digital presenceStago compliance and trust
Trust signalCompliance1 record
Stago financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stago leadership team
Management profileNumber of profiles
Profiles1 record
Stago subsidiaries and ownership
Company hierarchySubsidiaries6 records
Stago funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stago M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stago
What does Stago do?
Stago develops, manufactures, and supplies diagnostic instruments, reagents, and quality control solutions specialized in hemostasis and thrombosis testing for clinical laboratories and hospitals worldwide. Its portfolio spans the Max Generation analyzer suite, ST Genesia platform, TA-4V3/TA-8V3 Thrombo-Aggregometers, sthemO instrument line, the sthemE Qualiris external quality assessment program, and reagent products such as Anti-Xa and CY-QUANT MV-TF Activity.
Is Stago a public or private company?
Stago is a private company. It is classified as private equity controlled and is currently operating.
When was Stago founded?
Stago was founded in 1945. It employs 1,001 to 5,000 people.
Where is Stago based?
Stago is headquartered in Asnières, France, in the Europe region.
How does Stago make money?
One revenue line is on record: hemostasis Diagnostics Instruments and Reagents.
Who are Stago's main competitors?
Broad incumbents on record are Siemens Healthineers, Roche Diagnostics and Abbott Diagnostics. Direct peers are Werfen (Instrumentation Laboratory), Sysmex Corporation and Helena Laboratories. Emerging players are Trinity Biotech and Mindray. Others are QuidelOrtho and Bio-Rad Laboratories.
Does Stago have an API?
No public API is recorded for Stago.
What industry is Stago in?
Stago's product category is In Vitro Hemostasis Diagnostics. Its primary akta.pro industry code is HLAFAMAC, Hematology & Coagulation Laboratories, with a secondary code of HLAGAEAE, Clinical Chemistry, Hematology & Coagulation Testing (Trial Support). Its NAICS code is 621511 and its SIC code is 2835.